Drug Patents owned by Corcept Therap

1. List of Korlym drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921348 CORCEPT THERAP Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
Aug, 2028

(5 years from now)

US10842801 CORCEPT THERAP Optimizing mifepristone absorption
Nov, 2032

(9 years from now)

US10500216 CORCEPT THERAP Optimizing mifepristone absorption
Mar, 2033

(10 years from now)

US9943526 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients
Apr, 2036

(13 years from now)

US10166243 CORCEPT THERAP Optimizing mifepristone levels for cushing'S patients
Apr, 2036

(13 years from now)

US10660904 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients
Apr, 2036

(13 years from now)

US10166242 CORCEPT THERAP Optimizing mifepristone levels for Cushing's patients
Apr, 2036

(13 years from now)

US10006924 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent cushing's syndrome
Aug, 2036

(13 years from now)

US10495650 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Aug, 2036

(13 years from now)

US9829495 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Aug, 2036

(13 years from now)

US10151763 CORCEPT THERAP Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Jan, 2037

(13 years from now)

US10842800 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(14 years from now)

US10195214 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Jun, 2037

(14 years from now)

US10780097 CORCEPT THERAP Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

US10314850 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

US10231983 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in